Bone Biologics Q2 net loss widens 4.48% to $773,702

Reuters2026/08/14 21:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bone Biologics posted a Q2 net loss of USD 773,702, widening 4.48% from a year earlier.
Operating loss widened 8.02% to USD 808,106 as total operating expenses rose 8.02% to USD 808,106.
R&D expense climbed 61.13% to USD 308,747 due to development work to extend protein shelf-life.
G&A costs fell 10.26% to USD 499,359; interest income more than doubled to USD 34,512.
Cash totaled USD 4.03 million at June 30, 2026; a July 2026 private placement raised about USD 2.7 million net.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038482), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bone Biologics Q2 net loss widens 4.48% to $773,702

You may also like

Crypto prices